Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$3.01−0.08 (-2.59%)

Close on Nov 12, 2026Market cap $121.53MP/E –Yield –

Molecular Partners r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was CHF 40.19M, down 17.3% from the year before. The highest annual figure on record is CHF 56.08M in fiscal 2020.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	CHF 40.19M	-17.3%
FY2024	Dec 31, 2024	CHF 48.60M	-0.4%
FY2023	Dec 31, 2023	CHF 48.78M	-3.9%
FY2022	Dec 31, 2022	CHF 50.75M	-8.9%
FY2021	Dec 31, 2021	CHF 55.72M	-0.6%
FY2020	Dec 31, 2020	CHF 56.08M	+28.9%
FY2019	Dec 31, 2019	CHF 43.50M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	CHF 9.61M	-23.6%
Q2 FY2025	Jun 30, 2025	CHF 10.71M	–
Q2 FY2024	Jun 30, 2024	CHF 13.09M	–
Q2 FY2023	Jun 30, 2023	CHF 11.63M	–
Q2 FY2022	Jun 30, 2022	CHF 12.57M	–

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Revenue growth-100.0% · median -38.4%

Advertisement
300 × 250

See a number that looks wrong?